{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-034834","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2026-05-14T12:48:56+00:00","discovered_at":"2026-05-14T12:50:00.284142+00:00","generated_at":"2026-05-14T12:50:10.894789+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Senti Bio reports Q1 net loss $4.2M, secures up to $40M financing; FDA supports pivotal trial for SENTI-202 in R/R AML","bullets":["Net loss $4.2M ($0.14/share) vs $14.1M year ago; cash $8.9M as of March 31, 2026.","Secured up to $40M in senior secured convertible notes from Celadon Partners; initial $10M tranche expected May 2026.","FDA RMAT meeting supports single-arm multi-center pivotal trial for SENTI-202 in R/R AML after LD chemotherapy.","Donor X phenotype identified: 50% cCR (7/14) with Donor X NK cells vs 12.5% (1/8) without; longest remission 21+ months.","Lease modification gain $6.9M; cash burn reduced to $7.5M Q1 2026 from $14.1M Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-034834","json":"https://secwatch.observer/filing/0001628280-26-034834.json","markdown":"https://secwatch.observer/filing/0001628280-26-034834.md","text":"https://secwatch.observer/filing/0001628280-26-034834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/0001628280-26-034834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000162828026034834/snti-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:50:10.894789+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}